Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect

被引:184
作者
Vincent, L
Chen, W
Hong, L
Mirshahi, F
Mishal, Z
Mirshahi-Khorassani, T
Vannier, JP
Soria, J
Soria, C
机构
[1] Lab DIFEMA, UFR Med & Pharm Rouen, F-76183 Rouen, France
[2] Hop St Louis, INSERM, U553, Paris, France
[3] Hotel Dieu, Biochim Lab, Paris, France
[4] Hotel Dieu, EMI 99 12, Paris, France
关键词
anti-angiogenesis; migration; HMG-CoA reductase inhibitor; cerivastatin; RhoA; Ras;
D O I
10.1016/S0014-5793(01)02337-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have suggested that inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (statins) can play a role in protection against vascular risk, which is independent of cholesterol reduction. It could act by inhibiting the synthesis of isoprenoids (farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP)), which are respectively essential for membrane attachment and biological activity of GTPases Ras and RhoA. This study demonstrates that a statin (cerivastatin) inhibits angiogenesis, This effect was due to a decrease in endothelial cell locomotion which was reversed by GGPP, It was mainly related to delocalization of RhoA from cell membrane to cytoplasm, responsible for the disorganization of actin stress fibers. Furthermore, a decrease in MMP-2 secretion, involved in cell invasion, mas also observed. This effect is rather due to Ras inhibition as it was reversed by FPP, This antiangiogenic activity could explain the beneficial effect of statins on atherosclerosis and on cancer prevention as shown by clinical studies. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [31] Fluvastatin, HMG-CoA reductase inhibitor: Antiatherogenic profiles through its lipid-lowering-dependent and -independent actions
    Mitani, H
    Kimura, M
    CARDIOVASCULAR DRUG REVIEWS, 2000, 18 (04): : 284 - 303
  • [32] IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor
    Otsuki, T
    Sakaguchi, H
    Eto, M
    Fujii, T
    Hatayama, T
    Takata, A
    Tsujioka, T
    Sugihara, T
    Hyodoh, F
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (03) : 763 - 768
  • [33] The anti-apoptotic effects of HMG-CoA reductase inhibitors on vascular endothelial cells is mediated by ASK1 suppression
    Kataoka, Keiichiro
    Kim-Mitsuyama, Shokei
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (02) : 443 - 443
  • [34] Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits
    Kato, M
    Sada, T
    Mizuno, M
    Kitayama, K
    Inaba, T
    Koike, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (04) : 556 - 562
  • [35] HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis
    Kuwahara, Noriko
    Sasaki, Susumu
    Kobara, Miyuki
    Nakata, Tetsuo
    Tatsumi, Tetsuya
    Irie, Hidekazu
    Narumiya, Hiromichi
    Hatta, Tsuguru
    Takeda, Kazuo
    Matsubara, Hiroaki
    Hushiki, Shinji
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 123 (02) : 84 - 90
  • [36] HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation
    Al-Haidari, Amr A.
    Syk, Ingvar
    Thorlacius, Henrik
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (01) : 68 - 72
  • [37] HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro - Involvement of Rho GTPase-dependent mechanism
    Yoshida, M
    Sawada, T
    Ishii, H
    Gerszten, RE
    Rosenzweig, A
    Gimbrone, MA
    Yasukochi, Y
    Numano, F
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (07) : 1165 - 1171
  • [38] Statin activation of skeletal ryanodine receptors (RyR1) is a class effect but separable from HMG-CoA reductase inhibition
    Lindsay, Chris
    Musgaard, Maria
    Russell, Angela J.
    Sitsapesan, Rebecca
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (21) : 4941 - 4957
  • [39] CHARACTERIZATION OF HUMIDITY-DEPENDENT CHANGES IN CRYSTAL PROPERTIES OF A NEW HMG-COA REDUCTASE INHIBITOR IN SUPPORT OF ITS DOSAGE FORM DEVELOPMENT
    MORRIS, KR
    NEWMAN, AW
    BUGAY, DE
    RANADIVE, SA
    SINGH, AK
    SZYPER, M
    VARIA, SA
    BRITTAIN, HG
    SERAJUDDIN, ATM
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 108 (03) : 195 - 206
  • [40] A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action
    Sumi, D
    Hayashi, T
    Thakur, NK
    Jayachandran, M
    Asai, Y
    Kano, H
    Matsui, H
    Iguchi, A
    ATHEROSCLEROSIS, 2001, 155 (02) : 347 - 357